In a recent phase I clinical trial5 involving HLA-A2+ patients with HNSCC, patients were treated with a multiple CTL and T helper cell-defined, wt sequence p53 peptide-loaded DC-based adjuvant vaccination. The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.